** Shares of drugmaker Rigel Pharmaceuticals RIGL.O rise ~3% to $19.54
** RIGL says it has settled patent litigation with Annora Pharma regarding co's blood disorder drug, Tavalisse, to treat patients with immune thrombocytopenia $(ITP)$ who haven't responded adequately to prior treatments
** Lawsuit began when Annora submitted an application to the FDA to market a generic version of Tavalisse
** ITP is a condition where the immune system mistakenly attacks and destroys platelets, leading to a low platelet count and increased risk of bleeding
** Under the settlement, Annora will be allowed to sell its generic version starting in Q2 2032 or earlier under certain circumstances
** Annora did not immediately respond to Reuters' request for comment
** RIGL gained 33.6% in the last 12 months
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。